Neurology Central

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma


Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.